Citations 22

Nonlinear Z‐score modeling for improved detection of cognitive abnormality

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | December 5, 2019 | Volume: 11 | Issue: 1 | Pages: 797-808

10.1016/j.dadm.2019.08.003 | PMID 31872042

AbstractIntroductionConventional Z‐scores are generated by subtracting the mean and dividing by the standard deviation. More recent methods linearly correct for age, sex, and education, so that these “adjusted” Z‐scores better represent whether an individual's cognitive performance is abnormal. Extreme negative Z‐scores for individuals relative to this normative distribution are considered indicative of cognitive deficiency.MethodsIn this article, we consider nonlinear shape constrained additive models accounting for age, sex, and education (correcting for nonlinearity). Additional shape constrained additive models account for varying standard deviation of the cognitive scores with age (correcting for heterogeneity of variance).ResultsCorrected Z‐scores based on nonlinear shape constrained additive models provide improved adjustment for age, sex, and education, as indicated by higher adjusted‐R2.DiscussionNonlinearly corrected Z‐scores with respect to age, sex, and education with age‐varying residual standard deviation allow for improved detection of non‐normative extreme cognitive scores.
Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration

Alzheimer's & Dementia | November 26, 2019 | Volume: 16 | Issue: 1 | Pages: 49-59

10.1016/j.jalz.2019.08.196 | PMID 31784375

AbstractIntroductionThe Advancing Research and Treatment in Frontotemporal Lobar Degeneration and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects longitudinal studies were designed to describe the natural history of familial‐frontotemporal lobar degeneration due to autosomal dominant mutations.MethodsWe examined cognitive performance, behavioral ratings, and brain volumes from the first time point in 320 MAPT, GRN, and C9orf72 family members, including 102 non–mutation carriers, 103 asymptomatic carriers, 43 mildly/questionably symptomatic carriers, and 72 carriers with dementia.ResultsAsymptomatic carriers showed similar scores on all clinical measures compared with noncarriers but reduced frontal and temporal volumes. Those with mild/questionable impairment showed decreased verbal recall, fluency, and Trail Making Test performance and impaired mood and self‐monitoring. Dementia was associated with impairment in all measures. All MAPT carriers with dementia showed temporal atrophy, but otherwise, there was no single cognitive test or brain region that was abnormal in all subjects.DiscussionImaging changes appear to precede clinical changes in familial‐frontotemporal lobar degeneration, but specific early clinical and imaging changes vary across individuals.
P2‐329: TRACKING WHITE MATTER DEGENERATION IN ASYMPTOMATIC AND SYMPTOMATIC MAPT MUTATION CARRIERS WITH DTI

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_14 | Pages: No page available

10.1016/j.jalz.2019.06.2736

Frontal lobe 1 H MR spectroscopy in asymptomatic and symptomatic MAPT mutation carriers

Neurology | July 18, 2019 | Volume: 93 | Issue: 8 | Pages: No page available

10.1212/wnl.0000000000007961 | PMID 31315971

Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers

Journal of Neuroimaging | June 7, 2019 | Volume: 29 | Issue: 5 | Pages: 624-629

10.1111/jon.12642 | PMID 31173437

ABSTRACT BACKGROUND AND PURPOSE The objective of this study was to longitudinally investigate the trajectory of change in 1 H MRS measurements in asymptomatic MAPT mutation carriers who became symptomatic during follow‐up, and to determine the time at which the neurochemical alterations accelerated during disease progression. METHODS We identified eight MAPT mutations carriers who transitioned from asymptomatic to symptomatic disease during follow‐up. All participants were longitudinally followed with an average of 7.75 years (range 4‐11 years) and underwent two or more single voxel 1 H MRS examinations from the posterior cingulate voxel, with a total of 60 examinations. The rate of longitudinal change for each metabolite was estimated using linear mixed models. A flex point model was used to estimate the flex time point of the change in slope. RESULTS The decrease in the NAA/mI ratio accelerated 2.09 years prior to symptom onset, and continued to decline. A similar trajectory was observed in the presumed glial marker mI/Cr ratio accelerating 1.86 years prior to symptom onset. CONCLUSIONS Our findings support the potential use of longitudinal 1 H MRS for monitoring the neurodegenerative progression in MAPT mutation carriers starting from the asymptomatic stage.
O2‐14‐01: CHARACTERISTICS AND PROGRESS OF 320 SUBJECTS IN THE LONGITUDINAL EVALUATION OF FAMILIAL FRONTOTEMPORAL DEMENTIA SUBJECTS (LEFFTDS) PROTOCOL

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_12 | Pages: No page available

10.1016/j.jalz.2018.06.2718

O1‐08‐01: THE NIH‐EXAMINER IS SENSITIVE TO COGNITIVE CHANGES IN ASYMPTOMATIC AND MILDLY SYMPTOMATIC FAMILIAL FRONTOTEMPORAL DEMENTIA

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_4 | Pages: No page available

10.1016/j.jalz.2018.06.2372

P2‐430: MR SPECTROSCOPY FROM FRONTAL LOBE AND POSTERIOR CINGULATE GYRUS IN ASYMPTOMATIC AND SYMPTOMATIC MICROTUBULE‐ASSOCIATED PROTEIN TAU (MAPT) MUTATION CARRIERS

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_16 | Pages: No page available

10.1016/j.jalz.2018.06.1122

P1‐420: ACCELERATED NEUROCHEMICAL CHANGES PRIOR TO PHENOCONVERSION TO FRONTOTEMPORAL LOBAR DEGENERATION IN PRESYMPTOMATIC MICROTUBULE‐ASSOCIATED PROTEIN TAU (MAPT) MUTATION CARRIERS: A LONGITUDINAL MRS STUDY

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_8 | Pages: No page available

10.1016/j.jalz.2018.06.429

P1‐419: USING A BRAIN NETWORK APPROACH TO PREDICT GENETIC MUTATION IN INDIVIDUAL PATIENTS WITH FAMILIAL FRONTOTEMPORAL DEMENTIA

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_8 | Pages: No page available

10.1016/j.jalz.2018.06.428